<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034848</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2018-13</org_study_id>
    <nct_id>NCT05034848</nct_id>
  </id_info>
  <brief_title>Peripheral Artery Disease (PAD) : Its Effects on Bone</brief_title>
  <acronym>AMICOS</acronym>
  <official_title>Peripheral Artery Disease (PAD) : Its Effects on Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of PAD and osteoporosis (OP) both get higher with age. Clinical and epidemiologic&#xD;
      evidence have showed an increased cardiovascular risk in OP and bone loss and fragility&#xD;
      fractures in patient with cardiovascular disease.&#xD;
&#xD;
      This study will examine the relationship between vascular disease in legs and sBMD and vBMD&#xD;
      at trabecular and cortical sites and bone microarchitecture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of our study is to determinate if presence of PAD is associated with lower&#xD;
      sBMD and vBMD values at the tibias, assuming that BMD should be more alterate in the&#xD;
      predominant vascular impairement site.&#xD;
&#xD;
      Our secondary objectives are to :&#xD;
&#xD;
        -  determine if severity of PAD quantified by ankle brachial index ABI is associated to a&#xD;
           decrease of BMD values defined by T-Score at the left hip, spine and legs, but also with&#xD;
           volumetric values, assessed by HRpQCT at the non dominant radius and at both tibias.&#xD;
&#xD;
        -  determine the prevalence of osteoporosis in our population&#xD;
&#xD;
        -  To evaluate the relationships between ;&#xD;
&#xD;
        -  lipids and bone parameters&#xD;
&#xD;
        -  vit D and parathormone with PAD severity&#xD;
&#xD;
        -  levels of physical activity and both vascular and bone impairments&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>observational, interventional, non comparative, prospective, monocentric open study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) volumic values at the tibias of PAD (Peripheral Artery Disease) patients</measure>
    <time_frame>Day 0</time_frame>
    <description>BMD volumic values are BMD volumetric bone mineral density (mg HA/cm3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) measurement by DXA</measure>
    <time_frame>Day 0</time_frame>
    <description>Relations between areal BMD results (DXA) at the hip and lumbar spine and the ankle brachial index measured at the two legs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between microstructural parameters and ankle brachial index results</measure>
    <time_frame>Day 0</time_frame>
    <description>The following micro structural parameters assessed by HRpQCT at both tibias will be :&#xD;
Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3),&#xD;
Dinn : inner trabecular bone density (mg HA/cm3),&#xD;
Dmeta: metatrabecular bone density (mg HA/cm3),&#xD;
Dcort: volumetric cortical bone mineral density (mg HA/cm3),&#xD;
D100: total volumetric bone mineral density (mg HA/cm3),&#xD;
Tb.Th: trabecular thickness (mm),&#xD;
Tb.N: trabecular number (mm-1);&#xD;
Tb.Sp: trabecular separation (mm),&#xD;
Ct.Th: cortical thickness (mm);&#xD;
Tb1.NSD: intra-distribution individual separation (mm),&#xD;
BV / TV: trabecular bone volume (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between microstructural parameters at tibias</measure>
    <time_frame>Day 0</time_frame>
    <description>comparison between bone microarchitecture parameters at the tibia: the parameters will be compared between the most severely limb and the contralateral one.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Lipid and bone parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>We will study the relation between lipidic and bone parameters. Potential correlations between on the one hand (lipid parameters: total and HDL-cholesterol, triglyceridemia, LDL-cholesterol calculation) and on the other hand bone parameters: vBMD volumetric bone mineral density (mg HA/cm3) Ct.BMD: cortical volumetric bone mineral density (mg/cm3); Tb.BMD: trabecular volumetric bone mineral density (mg HA/cm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of densitometric osteoporotic patients</measure>
    <time_frame>Day 0</time_frame>
    <description>percentage of densitometric osteoporotic patients in the population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of risk of fracture</measure>
    <time_frame>Day 0</time_frame>
    <description>The risk of fracture at 10 years will be evaluate by the Fracture Risk Assessment Tool (FRAX) survey.&#xD;
The FRAX® tool was developed by the then WHO Collaborating Centre for Metabolic Bone Diseases (1991-2010) at the University of Sheffield. It was launched in 2008 following approximately 10 years of meta-analyses of a variety of risk factors for osteoporotic fracture. Although not the only fracture prediction tool available, FRAX® is the only risk calculator which has been calibrated to rates of fracture and mortality per individual country and has been shown to identify a risk amenable to available treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cardiovascular risk</measure>
    <time_frame>Day 0</time_frame>
    <description>Cardiovascular risk assessment using the SCORE tool (Systematic Coronary Risk Estimation).&#xD;
Four levels of risk are defined:&#xD;
Very high cardiovascular risk ≥ 10%;&#xD;
High risk, which includes subjects with major or particularly high risk factors (familial hypercholesterolemia, severe hypertension, etc.) and those with a score between 5 and 10%;&#xD;
Moderate risk, which concerns patients with a score between 1 and 5%;&#xD;
Low risk, which includes subjects with a score &lt; 1%;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between microstructural parameters at tibias and radius</measure>
    <time_frame>Day 0</time_frame>
    <description>comparison between bone microarchitecture at the tibia and of the radius.&#xD;
The following micro structural parameters assessed by HRpQCT at tibias and radius will be :&#xD;
Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3),&#xD;
Dinn : inner trabecular bone density (mg HA/cm3),&#xD;
Dmeta: metatrabecular bone density (mg HA/cm3),&#xD;
Dcort: volumetric cortical bone mineral density (mg HA/cm3),&#xD;
D100: total volumetric bone mineral density (mg HA/cm3),&#xD;
Tb.Th: trabecular thickness (mm),&#xD;
Tb.N: trabecular number (mm-1);&#xD;
Tb.Sp: trabecular separation (mm),&#xD;
Ct.Th: cortical thickness (mm);&#xD;
Tb1.NSD: intra-distribution individual separation (mm),&#xD;
BV / TV: trabecular bone volume (%).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bone</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>PAD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assessment of BMD by DXA and HRpQCT</intervention_name>
    <description>DXA : BMD assessment at the left hip, rachis and both legs&#xD;
HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs&#xD;
Biological samples</description>
    <arm_group_label>PAD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PAD patients defined by an Ankle brachial index &lt; 0.9&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Patient affiliated with a social security organism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy&#xD;
&#xD;
          -  Patients Under guardianship&#xD;
&#xD;
          -  Patient with known PAD who had been previously treated by surgery or endovascular&#xD;
             pathway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LESPESSAILLES, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Orleans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie POUGOUE TOUKO</last_name>
    <phone>+33238744086</phone>
    <email>elodie.pougoue-touko@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LESPESSAILLES, Ph</last_name>
      <email>eric.lespessailles@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LESPESSAILLES, Ph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bréban S, Benhamou CL, Chappard C. Dual-energy X-ray absorptiometry assessment of tibial mid-third bone mineral density in young athletes. J Clin Densitom. 2009 Jan-Mar;12(1):22-7. doi: 10.1016/j.jocd.2008.10.009. Epub 2008 Dec 25.</citation>
    <PMID>19111489</PMID>
  </reference>
  <reference>
    <citation>Collins TC, Ewing SK, Diem SJ, Taylor BC, Orwoll ES, Cummings SR, Strotmeyer ES, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation. 2009 May 5;119(17):2305-12. doi: 10.1161/CIRCULATIONAHA.108.820993. Epub 2009 Apr 20.</citation>
    <PMID>19380619</PMID>
  </reference>
  <reference>
    <citation>Fehérvári M, Sarkadi H, Krepuska M, Sótonyi P, Acsády G, Entz L, Lakatos P, Szeberin Z. Bone mineral density is associated with site-specific atherosclerosis in patients with severe peripheral artery disease. Calcif Tissue Int. 2013 Jul;93(1):55-61. doi: 10.1007/s00223-013-9727-5. Epub 2013 Apr 6.</citation>
    <PMID>23564349</PMID>
  </reference>
  <reference>
    <citation>Gaudio A, Muratore F, Fiore V, Rapisarda R, Signorelli SS, Fiore CE. Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease. Osteoporos Int. 2015 Jun;26(6):1747-53. doi: 10.1007/s00198-015-3057-6. Epub 2015 Feb 12.</citation>
    <PMID>25672808</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>HRpQCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

